Lyndra’s long-acting risperidone formulation hits PhIII schizophrenia trial endpoints

Lyndra Therapeutics’ schizophrenia drug candidate has passed its late-stage clinical test according to interim data, prompting an early end to the study and preparations for a registrational safety trial.

The Phase III STARLYNG-1 trial was designed to test once-weekly LYN-005 against standard of care daily Risperdal…
Click here to view original post

Advertisement — Advertise with Biotech Networks